Realizing the Full Promise of Self-Amplifying RNA
Oncorus is focused on IV-administered, self-amplifying RNA medicines to transform outcomes for cancer patients — safely killing tumor cells and stimulating the immune system to better fight cancer.
IV-Administered. Self-Amplifying. Tumor-Targeted.
Our saRNA platform is designed to be administered intravenously, enabling systemic delivery to tumors throughout the body — a critical advantage over locally-injected approaches.
Self-amplifying RNA uniquely expands within target cells, producing sustained therapeutic protein expression from a single low dose — maximizing efficacy while minimizing systemic exposure.
By simultaneously killing tumor cells and activating multiple arms of the immune system, our approach creates a coordinated anti-tumor response with the potential for durable remission.
Platform Capabilities
Systemic IV Delivery
Engineered for intravenous administration, enabling access to disseminated tumors and metastatic disease that localized therapies cannot reach.
Self-Amplifying Expression
saRNA replicates within target cells, producing high-level, sustained therapeutic protein expression from a fraction of the dose required by conventional mRNA.
Multi-Arm Immune Activation
Designed to engage innate and adaptive immunity simultaneously — stimulating T cells, NK cells, and cytokine pathways to mount a coordinated anti-tumor response.
Clinical Pipeline
Transforming Outcomes for Cancer Patients
Our science is built on the conviction that self-amplifying RNA represents a fundamentally new class of cancer medicine — one capable of addressing the limitations of existing immunotherapies.